Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 15/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904343 | 0.94 | CYP1A2 (0.68) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL15109234 | 0.93 | CYP1A2 (0.67) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| Deleobuvir SCHEMBL900174 | 0.93 | CYP1A2 (0.76) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| Deleobuvir SCHEMBL900176 | 0.93 | CYP1A2 (0.76) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| Deleobuvir SCHEMBL29379674 | 0.93 | CYP1A2 (0.76) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL15109353 | 0.93 | CYP1A2 (0.76) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL15109258 | 0.89 | CYP1A2 (0.62) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL13680374 | 0.89 | CYP1A2 (0.62) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL15109298 | 0.88 | CYP1A2 (0.61) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL15109363 | 0.88 | CYP1A2 (0.70) | CYP1A2CYP2C8CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| WO-2012044520-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | HAVCR2, EIF2AK2, SLC10A1 | CYP1A2 2933/4885CYP2C8 2071/4885CYP3A4 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.